Virus-derived peptide inhibitors of the herpes simplex virus type 1 nuclear egress complex

Abstract Herpesviruses infect a majority of the human population, establishing lifelong latent infections for which there is no cure. Periodic viral reactivation spreads infection to new hosts while causing various disease states particularly detrimental in the immunocompromised. Efficient viral rep...

Full description

Bibliographic Details
Main Authors: Elizabeth B. Draganova, Ekaterina E. Heldwein
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-83402-x
id doaj-5dc9c39447a54f43b26531225b79a2c5
record_format Article
spelling doaj-5dc9c39447a54f43b26531225b79a2c52021-02-21T12:31:46ZengNature Publishing GroupScientific Reports2045-23222021-02-0111111010.1038/s41598-021-83402-xVirus-derived peptide inhibitors of the herpes simplex virus type 1 nuclear egress complexElizabeth B. Draganova0Ekaterina E. Heldwein1Department of Molecular Biology and Microbiology, Tufts University School of MedicineDepartment of Molecular Biology and Microbiology, Tufts University School of MedicineAbstract Herpesviruses infect a majority of the human population, establishing lifelong latent infections for which there is no cure. Periodic viral reactivation spreads infection to new hosts while causing various disease states particularly detrimental in the immunocompromised. Efficient viral replication, and ultimately the spread of infection, is dependent on the nuclear egress complex (NEC), a conserved viral heterodimer that helps translocate viral capsids from the nucleus to the cytoplasm where they mature into infectious virions. Here, we have identified peptides, derived from the capsid protein UL25, that are capable of inhibiting the membrane-budding activity of the NEC from herpes simplex virus type 1 in vitro. We show that the inhibitory ability of the peptides depends on their length and the propensity to form an α-helix but not on the exact amino acid sequence. Current therapeutics that target viral DNA replication machinery are rendered ineffective by drug resistance due to viral mutations. Our results establish a basis for the development of an alternative class of inhibitors against nuclear egress, an essential step in herpesvirus replication, potentially expanding the current repertoire of available therapeutics.https://doi.org/10.1038/s41598-021-83402-x
collection DOAJ
language English
format Article
sources DOAJ
author Elizabeth B. Draganova
Ekaterina E. Heldwein
spellingShingle Elizabeth B. Draganova
Ekaterina E. Heldwein
Virus-derived peptide inhibitors of the herpes simplex virus type 1 nuclear egress complex
Scientific Reports
author_facet Elizabeth B. Draganova
Ekaterina E. Heldwein
author_sort Elizabeth B. Draganova
title Virus-derived peptide inhibitors of the herpes simplex virus type 1 nuclear egress complex
title_short Virus-derived peptide inhibitors of the herpes simplex virus type 1 nuclear egress complex
title_full Virus-derived peptide inhibitors of the herpes simplex virus type 1 nuclear egress complex
title_fullStr Virus-derived peptide inhibitors of the herpes simplex virus type 1 nuclear egress complex
title_full_unstemmed Virus-derived peptide inhibitors of the herpes simplex virus type 1 nuclear egress complex
title_sort virus-derived peptide inhibitors of the herpes simplex virus type 1 nuclear egress complex
publisher Nature Publishing Group
series Scientific Reports
issn 2045-2322
publishDate 2021-02-01
description Abstract Herpesviruses infect a majority of the human population, establishing lifelong latent infections for which there is no cure. Periodic viral reactivation spreads infection to new hosts while causing various disease states particularly detrimental in the immunocompromised. Efficient viral replication, and ultimately the spread of infection, is dependent on the nuclear egress complex (NEC), a conserved viral heterodimer that helps translocate viral capsids from the nucleus to the cytoplasm where they mature into infectious virions. Here, we have identified peptides, derived from the capsid protein UL25, that are capable of inhibiting the membrane-budding activity of the NEC from herpes simplex virus type 1 in vitro. We show that the inhibitory ability of the peptides depends on their length and the propensity to form an α-helix but not on the exact amino acid sequence. Current therapeutics that target viral DNA replication machinery are rendered ineffective by drug resistance due to viral mutations. Our results establish a basis for the development of an alternative class of inhibitors against nuclear egress, an essential step in herpesvirus replication, potentially expanding the current repertoire of available therapeutics.
url https://doi.org/10.1038/s41598-021-83402-x
work_keys_str_mv AT elizabethbdraganova virusderivedpeptideinhibitorsoftheherpessimplexvirustype1nuclearegresscomplex
AT ekaterinaeheldwein virusderivedpeptideinhibitorsoftheherpessimplexvirustype1nuclearegresscomplex
_version_ 1724257918052728832